Kathleen M. Neuzil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kathleen M. Neuzil has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Duncan Steele
Enterics, Diagnostics, Genomics & Epidemiology, Gates Foundation, Seattle, WA 98109, USA
4 shared publications - John C. Victor
PATH, Seattle, Washington
3 shared publications - Khalequ Zaman
International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh
3 shared publications George Armah
2 shared publications- Htay Htay Han
GlaxoSmithKline Vaccines; Philadelphia, PA USA
2 shared publications - Janet A. Englund
Department of Pediatrics, University of Washington, Seattle Children’s Research Institute , Seattle, Washington
2 shared publications
Latest Publications
- 1 January 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (1) , 3-5
Influenza Vaccination of Pregnant Women and Protection of Their Infants
Seasonal influenza vaccination for parturients is recommended because of their increased susceptibility to severe disease. The efficacy of inactivated influenza vaccine (IIV) in pregnant women may differ from that in healthy nonpregnant women or in men and could be more accentuated in parturients infected with HIV because of immunosuppression. This study comprised 2 blinded randomized controlled trials of trivalent IIV (IIV3) in parturients with and without HIV infection to evaluate safety, immunogenicity, and efficacy of IIV3 in these women and their infants to 24 weeks postpartum. The women were aged 18 to 38 years, with estimated gestations of 20 to 36 weeks. The primary objectives for women without HIV infection were to evaluate the efficacy of IIV3 vaccination during pregnancy in protecting their infants against influenza through 24 weeks postpartum and to compare seroconversion rates between IIV3 recipients and placebo recipients 1 month after vaccination. In women with HIV, another objective was to evaluate the immunogenicity of IIV3 along with determining vaccine efficacy in mothers and their infants until 24 weeks postpartum. All mothers and infants in the HIV-infected cohort and a nested group of 180 HIV-uninfected mother-infant dyads were enrolled in a safety and immunogenicity study. Intention-to-treat and per-protocol analyses were conducted. Among 2116 black African non–HIV-infected parturients, 1062 and 1054 received IIV3 and placebo, respectively; 1026 and 1023 live infants were born to IIV3 and placebo recipients, respectively. Of 194 HIV-infected parturients, 100 received IIV3 and 94 received placebo. Of the 376 participants in the immunogenicity subset, 142 IIV3 and 148 placebo recipients were included in the per-protocol analysis. Postvaccination geometric mean titers increased from baseline by a factor of 6 to 10 in IIV3 recipients and were significantly higher than titers in placebo recipients. A greater proportion of IIV3 recipients had seroprotective hemagglutination inhibition (HAI) titers after vaccination compared with placebo recipients. Newborns of IIV3 recipients had higher HAI geometric mean titers than newborns of placebo recipients and were more likely to have an HAI titer of 1:40 or greater. The newborn-to-maternal ratios of HAI titers were 0.7 to 1.0 and were similar between study groups. In the HIV-infected women in the per-protocol immunogenicity arm, receipt of IIV3 resulted in increases in geometric mean titers of antibodies. A higher proportion of IIV3 recipients had seroprotective HAI titers after vaccination compared with placebo recipients. Newborns of IIV3 recipients had higher HAI geometric mean titers than did newborns of placebo recipients. The ratio of geometric mean HAI titers was 0.7 to 1.4. In the IIV3 group, titers for HAI were higher than those in the placebo group. Attack rates for influenza among the IIV3 recipients was lower as compared with the placebo recipients, 1.8% versus 3.6%, respectively, indicating a vaccine efficacy of 50.4% (95% confidence interval [CI], 14.5%–71.2%). Similarly, the attack rate was 1.9% for infants whose mothers were IIV3 recipients compared with 3.6% for those whose mothers received placebo; vaccine efficacy was 48.8% (95% CI, 11.6%–70.4%). Vaccine efficacy estimates in the per-protocol analysis were similar to the estimates in the intention-to-treat analysis. In the HIV-infected mothers, the attack rate was 7.0% in IIV3 recipients compared with 17.0% for placebo recipients, for an adjusted vaccine efficacy of 57.7% (95% CI, 0.2%–82.1%). The attack rates were 5.0% and 6.8% among infants of IIV3 and placebo recipients, respectively (efficacy, 26.7%; P = 0.60). Injection-site reactions were more frequent among IIV3 recipients in both cohorts, but no other significant differences in reactions were found. No significant between-group differences were found for rates of miscarriage, stillbirth, or premature birth or birth weight in the HIV-uninfected or -infected cohort. These results support the current World Health Organization recommendations for influenza vaccination during pregnancy, with a reduction in confirmed cases of influenza in both cohorts. Trivalent IIV was safe and immunogenic in HIV-uninfected and HIV-infected women. Because the study was conducted at a single center, the generalizability of the findings must be corroborated.
- 1 January 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (1) , 3-5
Influenza Vaccination of Pregnant Women and Protection of Their Infants
Seasonal influenza vaccination for parturients is recommended because of their increased susceptibility to severe disease. The efficacy of inactivated influenza vaccine (IIV) in pregnant women may differ from that in healthy nonpregnant women or in men and could be more accentuated in parturients infected with HIV because of immunosuppression. This study comprised 2 blinded randomized controlled trials of trivalent IIV (IIV3) in parturients with and without HIV infection to evaluate safety, immunogenicity, and efficacy of IIV3 in these women and their infants to 24 weeks postpartum. The women were aged 18 to 38 years, with estimated gestations of 20 to 36 weeks. The primary objectives for women without HIV infection were to evaluate the efficacy of IIV3 vaccination during pregnancy in protecting their infants against influenza through 24 weeks postpartum and to compare seroconversion rates between IIV3 recipients and placebo recipients 1 month after vaccination. In women with HIV, another objective was to evaluate the immunogenicity of IIV3 along with determining vaccine efficacy in mothers and their infants until 24 weeks postpartum. All mothers and infants in the HIV-infected cohort and a nested group of 180 HIV-uninfected mother-infant dyads were enrolled in a safety and immunogenicity study. Intention-to-treat and per-protocol analyses were conducted. Among 2116 black African non–HIV-infected parturients, 1062 and 1054 received IIV3 and placebo, respectively; 1026 and 1023 live infants were born to IIV3 and placebo recipients, respectively. Of 194 HIV-infected parturients, 100 received IIV3 and 94 received placebo. Of the 376 participants in the immunogenicity subset, 142 IIV3 and 148 placebo recipients were included in the per-protocol analysis. Postvaccination geometric mean titers increased from baseline by a factor of 6 to 10 in IIV3 recipients and were significantly higher than titers in placebo recipients. A greater proportion of IIV3 recipients had seroprotective hemagglutination inhibition (HAI) titers after vaccination compared with placebo recipients. Newborns of IIV3 recipients had higher HAI geometric mean titers than newborns of placebo recipients and were more likely to have an HAI titer of 1:40 or greater. The newborn-to-maternal ratios of HAI titers were 0.7 to 1.0 and were similar between study groups. In the HIV-infected women in the per-protocol immunogenicity arm, receipt of IIV3 resulted in increases in geometric mean titers of antibodies. A higher proportion of IIV3 recipients had seroprotective HAI titers after vaccination compared with placebo recipients. Newborns of IIV3 recipients had higher HAI geometric mean titers than did newborns of placebo recipients. The ratio of geometric mean HAI titers was 0.7 to 1.4. In the IIV3 group, titers for HAI were higher than those in the placebo group. Attack rates for influenza among the IIV3 recipients was lower as compared with the placebo recipients, 1.8% versus 3.6%, respectively, indicating a vaccine efficacy of 50.4% (95% confidence interval [CI], 14.5%–71.2%). Similarly, the attack rate was 1.9% for infants whose mothers were IIV3 recipients compared with 3.6% for those whose mothers received placebo; vaccine efficacy was 48.8% (95% CI, 11.6%–70.4%). Vaccine efficacy estimates in the per-protocol analysis were similar to the estimates in the intention-to-treat analysis. In the HIV-infected mothers, the attack rate was 7.0% in IIV3 recipients compared with 17.0% for placebo recipients, for an adjusted vaccine efficacy of 57.7% (95% CI, 0.2%–82.1%). The attack rates were 5.0% and 6.8% among infants of IIV3 and placebo recipients, respectively (efficacy, 26.7%; P = 0.60). Injection-site reactions were more frequent among IIV3 recipients in both cohorts, but no other significant differences in reactions were found. No significant between-group differences were found for rates of miscarriage, stillbirth, or premature birth or birth weight in the HIV-uninfected or -infected cohort. These results support the current World Health Organization recommendations for influenza vaccination during pregnancy, with a reduction in confirmed cases of influenza in both cohorts. Trivalent IIV was safe and immunogenic in HIV-uninfected and HIV-infected women. Because the study was conducted at a single center, the generalizability of the findings must be corroborated.
- Open Access
- 21 November 2014
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 211 (10) , 1517-1518
How Can We Solve the Enigma of Influenza Vaccine-Induced Protection?
(See the major article by Ohmit et al on pages 1519–28.)
- 21 November 2014
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 211 (10) , 1517-1518
Open AccessHow Can We Solve the Enigma of Influenza Vaccine-Induced Protection?
(See the major article by Ohmit et al on pages 1519–28.)
- Open Access
- 13 November 2013
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 58 (3) , 328-329
Editorial Commentary: Annual Studies of Influenza Vaccine Effectiveness: Evaluating Performance, Informing Policy, and Generating New Questions
- 13 November 2013
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 58 (3) , 328-329
Open AccessEditorial Commentary: Annual Studies of Influenza Vaccine Effectiveness: Evaluating Performance, Informing Policy, and Generating New Questions
- Open Access
- 13 November 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (2) , 505-511
Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis
Clinical trials of the human rotavirus vaccine Rotarix™ (RV1) have demonstrated significant reductions in severe rotavirus gastroenteritis (RVGE) in children worldwide. However, no correlate of vaccine efficacy (VE) has yet been established. This paper presents 2 analyses which aimed to investigate whether serum anti-RV IgA measured by ELISA 1 or 2 mo post-vaccination can serve as a correlate of efficacy against RVGE: (1) In a large Phase III efficacy trial (Rota-037), the Prentice criteria for surrogate endpoints was applied to anti-RV IgA seropositivity 1 mo post-vaccination. These criteria determine whether a significant vaccine group effect can be predicted from the surrogate, namely seropositivity (anti-RV IgA concentration >20 U/mL); (2) Among other GSK-sponsored RV1 VE studies, 8 studies which assessed immunogenicity at 1 or 2 mo post-vaccination in all or a sub-cohort of enrolled subjects and had at least 10 RVGE episodes were included in a meta-analysis to measure the regression between clinical VE and VE predicted from immunogenicity (VE1). In Rota-037, anti-RV IgA seropositivity post-vaccination was associated with a lower incidence of any or severe RVGE, however, the proportion of vaccine group effect explained by seropositivity was only 43.6% and 32.7% respectively. This low proportion was due to the vaccine group effect observed in seronegative subjects. In the meta-analysis, the slope of the regression between clinical VE and VE1 was statistically significant. These two independent analyses support the hypothesis that post-vaccination anti-RV IgA seropositivity (antibody concentration ≥20 U/mL) may serve as a useful correlate of efficacy in clinical trials of RV1 vaccines.
- 13 November 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (2) , 505-511
Open AccessAssociation of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis
Clinical trials of the human rotavirus vaccine Rotarix™ (RV1) have demonstrated significant reductions in severe rotavirus gastroenteritis (RVGE) in children worldwide. However, no correlate of vaccine efficacy (VE) has yet been established. This paper presents 2 analyses which aimed to investigate whether serum anti-RV IgA measured by ELISA 1 or 2 mo post-vaccination can serve as a correlate of efficacy against RVGE: (1) In a large Phase III efficacy trial (Rota-037), the Prentice criteria for surrogate endpoints was applied to anti-RV IgA seropositivity 1 mo post-vaccination. These criteria determine whether a significant vaccine group effect can be predicted from the surrogate, namely seropositivity (anti-RV IgA concentration >20 U/mL); (2) Among other GSK-sponsored RV1 VE studies, 8 studies which assessed immunogenicity at 1 or 2 mo post-vaccination in all or a sub-cohort of enrolled subjects and had at least 10 RVGE episodes were included in a meta-analysis to measure the regression between clinical VE and VE predicted from immunogenicity (VE1). In Rota-037, anti-RV IgA seropositivity post-vaccination was associated with a lower incidence of any or severe RVGE, however, the proportion of vaccine group effect explained by seropositivity was only 43.6% and 32.7% respectively. This low proportion was due to the vaccine group effect observed in seronegative subjects. In the meta-analysis, the slope of the regression between clinical VE and VE1 was statistically significant. These two independent analyses support the hypothesis that post-vaccination anti-RV IgA seropositivity (antibody concentration ≥20 U/mL) may serve as a useful correlate of efficacy in clinical trials of RV1 vaccines.
- 23 October 2013
- Published by American Medical Association (AMA) in JAMA
- Vol. 310 (16) , 1681-1682
Influenza Vaccination in 2013-2014
Every year, the public and health care system experience clinical and financial consequences of influenza epidemics. Influenza infection leads to hospitalizatio
- 23 October 2013
- Published by American Medical Association (AMA) in JAMA
- Vol. 310 (16) , 1681-1682
Influenza Vaccination in 2013-2014
Every year, the public and health care system experience clinical and financial consequences of influenza epidemics. Influenza infection leads to hospitalizatio
- Open Access
- 13 September 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 213
Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial
Rotaviruses are the most important cause of severe acute gastroenteritis worldwide in children <5 years of age. The human, G1P[8] rotavirus vaccine Rotarix™ significantly reduced severe rotavirus gastroenteritis episodes in a Phase III clinical trial conducted in infants in South Africa and Malawi. This paper examines rotavirus vaccine efficacy in preventing severe rotavirus gastroenteritis, during infancy, caused by the various G and P rotavirus types encountered during the first rotavirus-season.
- 13 September 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 213
Open AccessHuman rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial
Rotaviruses are the most important cause of severe acute gastroenteritis worldwide in children <5 years of age. The human, G1P[8] rotavirus vaccine Rotarix™ significantly reduced severe rotavirus gastroenteritis episodes in a Phase III clinical trial conducted in infants in South Africa and Malawi. This paper examines rotavirus vaccine efficacy in preventing severe rotavirus gastroenteritis, during infancy, caused by the various G and P rotavirus types encountered during the first rotavirus-season.
- 1 August 2012
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 11 (8) , 939-947
PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries
Expert Rev. Vaccines 11(8), 939-947 (2012) The 2009 influenza A/H1N1 pandemic demonstrated that a pandemic influenza virus has the potential to spread more rapidly in today's highly interconnected world than in the past. While pandemic morbidity and mortality are likely to be greatest in low-resource countries, manufacturing capacity and access to influenza vaccines predominantly exist in countries with greater resources and infrastructure. Even with recently expanded manufacturing capacity, the number of doses available within a 6-month timeframe would be inadequate to fully immunize the global population if the decision to implement a global vaccination program were made today. Improved, affordable vaccines are needed to limit the consequences of a global influenza outbreak and protect low-resource populations. PATH's Influenza Vaccine Project is supporting a range of activities in collaboration with private- and public-sector partners to advance the development of promising influenza vaccines that can be accessible and affordable for people in low-resource countries.
- 1 August 2012
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 11 (8) , 939-947
PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries
Expert Rev. Vaccines 11(8), 939-947 (2012) The 2009 influenza A/H1N1 pandemic demonstrated that a pandemic influenza virus has the potential to spread more rapidly in today's highly interconnected world than in the past. While pandemic morbidity and mortality are likely to be greatest in low-resource countries, manufacturing capacity and access to influenza vaccines predominantly exist in countries with greater resources and infrastructure. Even with recently expanded manufacturing capacity, the number of doses available within a 6-month timeframe would be inadequate to fully immunize the global population if the decision to implement a global vaccination program were made today. Improved, affordable vaccines are needed to limit the consequences of a global influenza outbreak and protect low-resource populations. PATH's Influenza Vaccine Project is supporting a range of activities in collaboration with private- and public-sector partners to advance the development of promising influenza vaccines that can be accessible and affordable for people in low-resource countries.